Recro Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Recro Pharma (REPH) Misses Q2 EPS by 10c, Revenues Miss
August 10, 2020 7:09 AM EDTRecro Pharma (NASDAQ: REPH) reported Q2 EPS of ($0.26), $0.10 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $15.52 million versus the consensus estimate of $18.88 million.
As the global COVID-19 situation continues to evolve, we have implemented new ways of working, and our concerns remain the health and safety of our associates, our customers, and the patients treated with the products we manufacture as well as our shareholders, said Gerri... More



